pharmaphorum
JANUARY 9, 2022
US medical device company Abbott has said it plans to launch a new range of ‘biowearable’ health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring. The company’s chief executive – Robert Ford – made the announcement at the massive CES tech trade show in Las Vegas, a venue usually dedicated to new TVs, gaming equipment, new smartphones and the like.
Pharma Times
JANUARY 11, 2022
The partnership between Oxford University and SEEQC promises to accelerate the use of quantum computing within pharmaceutical research in order to reduce the development time required for drug production worldwide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
JANUARY 12, 2022
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern Universityâs Shirley Ryan AbilityLab.
NY Times
JANUARY 14, 2022
A federal judge found that Mr. Shkreli violated state and federal antitrust laws by trying to maintain a monopoly over a lifesaving drug and must pay back the excess profits.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JANUARY 11, 2022
With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of their mRNA-based shots that are tailored to the new variant. Pfizer has said that a COVID-19 jab specifically targeting Omicron, as well as other existing variants, will begin human trials later this month and could be available as early as March.
Pharma Times
JANUARY 13, 2022
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Patent Watch
JANUARY 12, 2022
This chart shows the pharmaceutical companies with the most patents in Mexico. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Mexico? appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 14, 2022
The European Commission, EMA and national regulators within the EU have launched an initiative to change the way clinical trials are designed and run in order to position the bloc as an international “focal point” for clinical research. The broad strokes of the proposals are laid out in a document entitled Accelerating Clinical Trials in the EU (ACT EU) that lists priority actions that will be taken, including measures to allow greater use of innovative clinical trial designs.
Pharma Times
JANUARY 11, 2022
There is currently no cure for cystic fibrosis (CF), a debilitating, progressive condition with over 10,830 people in the UK currently diagnosed with the disease.
Outsourcing Pharma
JANUARY 13, 2022
With the amount of available data increasing and technology evolving, says a company leader, the job of data manager is more demanding than ever before.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Drug Channels
JANUARY 10, 2022
PCMA Business Forum. February 28 – March 1, 2022 JW Marriott Grande Lakes | Orlando, FL Register Today! www.pcma.com/businessforum. The PCMA Business Forum is PCMA's largest business networking and educational conference. PCMA’s PBM Members send a large number of executives from relevant business units including pharma and trade relations, specialty pharmacy, clinical and patient care services, and the c-suite.
pharmaphorum
JANUARY 12, 2022
Roche has launched what it says is a first-of-its kind handheld glucose management device, backed up by a digital platform that aims to simplify the work of doctors and nurses as they deliver care to patients. The cobas pulse system is a point-of-care device that combines a glucose test strip reader with a touch screen that is used for displaying patient information and data, as well as analysing and sharing clinical results.
Pharma Times
JANUARY 12, 2022
Under current guidelines, individuals that test positive for COVID-19 may be able to leave self-isolation after 7 days if certain conditions are met.
Outsourcing Pharma
JANUARY 14, 2022
The World Health Organization has recommended the drugs for COVID-19 patients, broadening the range of therapies to combat the virus behind the pandemic.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
NY Times
JANUARY 11, 2022
A former Africa correspondent, who covered the height of the AIDS epidemic there 15 years ago, finds lessons in the remarkable progress against that virus for our current fight.
pharmaphorum
JANUARY 14, 2022
Japanese pharma group Otsuka has led a $10 million first-round financing of GrayMatters Health, an Israeli company developing a digital health approach to the management of mental illness. Otsuka Medical Devices is also taking some rights to GrayMatters’ platform – called Prism – in Japan and some other Asian countries in connection with the financing, which was supported by Joy Ventures, J-Ventures, J-Impact, and existing backers Marius Nacht and Joyance Ventures.
Pharma Times
JANUARY 14, 2022
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation
Outsourcing Pharma
JANUARY 12, 2022
The pharma firm and collaborator Molecular Partners reported positive data out of their Phase II study for ensovibep, an antiviral for treating the virus.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Patent Watch
JANUARY 14, 2022
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs…. The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 13, 2022
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study. The report from Berkeley Research Group (BRG) – which was funded by the pharma industry trade group PhRMA – reveals a steady decrease in the proportion received by drugmakers from around 67% in 2013 to 49.5% in 2020.
Pharma Times
JANUARY 12, 2022
The test is hoped to provide patients with a more convenient means of access to treatment for respiratory issues.
Drug Channels
JANUARY 14, 2022
Today’s guest post comes from Jeremy Docken, Founder and Chief Strategy Officer at Kalderos. Jeremy describes Kalderos’ 340B rebate model. He discusses an independent research organization’s study of the 340B rebate model’s impact on covered entities’ cash flow. To learn more, download the whitepaper: The Kalderos 340B Rebate Model In Action: Ensuring a Thriving and Sustainable 340B Program.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Drug Patent Watch
JANUARY 8, 2022
This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 10, 2022
The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Ben Hargreaves takes a look at how the space is currently progressing and in what direction it could be heading in future. The pandemic brought about an interesting phenomenon for the pharmaceutical industry: there is a much greater awareness of both individual companies within the industry and their individua
Pharma Times
JANUARY 13, 2022
Despite diagnosis and treatment options improving for the rare kidney condition, further action is urgently required.
Drug Channels
JANUARY 11, 2022
As I have highlighted in previous posts, retail pharmacies are experiencing a period of intense competition that continues to pressure prescription profits. What's more, the pharmacy shakeout is accelerating, as smaller competitors exit and larger companies reduce store count. . In the video below, I provide a brief overview of key challenges facing retail pharmacy this year.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
NY Times
JANUARY 14, 2022
After one of his sons fell into a deep depression, he helped him recover. He later licensed an antidepressant that was a boon to his pharmaceutical company.
pharmaphorum
JANUARY 12, 2022
The development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the key players – Sarepta – thinks it may have the clinical data needed to file for regulator approval. The new data from the mid-stage Study 102 of SRP-9001 (delandistrogene moxeparvovec) comes from 21 patients who were initially in the placebo group of the study but crossed over to receive the gene therapy later.
Eye on FDA
JANUARY 12, 2022
Each year we look back to take stock of how the agency has been communicating in the course of the previous year and assess how that might compare to years gone by. In fact from year to year, there is a good deal of change that occurs. When Dr. Scott Gottlieb took the reins of FDA as Commissioner, the amount of communications material put out jumped enormously.
Pharma Times
JANUARY 10, 2022
The chronic, inflammatory disease affects an estimated 24 in every 10,000 people.
NY Times
JANUARY 11, 2022
If the preliminary decision is finalized this spring, it would sharply limit the number of patients who use the expensive drug.
Expert insights. Personalized for you.
145 
Let's personalize your content